REFERENCES
1. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:5888.
2. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72-82.
3. Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-90.
4. Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
5. Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50:101506.
6. Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome? Metab Target Organ Damage. 2024;4:10.
7. Duseja A, Singh SP, De A, et al. Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). J Clin Exp Hepatol. 2023;13:273-302.
8. Kaya E, Yilmaz Y. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2022;13:20420188221139650.
9. Huang XJ, Yin M, Zhou BQ, Tan XY, Xia YQ, Qin CX. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. World J Hepatol. 2023;15:985-1000.
10. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76-7.
11. Vaidya SR, Aeddula NR. Chronic renal failure. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535404/ [Last accessed on 1 Apr 2024].
12. Ryu H, Hong Y, Kang E, et al. KNOW-CKD Study Group. Comparison of outcomes of chronic kidney disease based on etiology: a prospective cohort study from KNOW-CKD. Sci Rep. 2023;13:3570.
13. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-74.
14. Ndumele CE, Rangaswami J, Chow SL, et al. American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the american heart association. Circulation. 2023;148:1606-35.
15. Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18:696-707.
16. Zoccali C, Mallamaci F, Adamczak M, et al. Cardiovascular complications in chronic kidney disease: a review from the European renal and cardiovascular medicine working group of the European renal association. Cardiovasc Res. 2023;119:2017-32.
17. Luo M, Cai J, Luo S, et al. Causal effects of gut microbiota on the risk of chronic kidney disease: a Mendelian randomization study. Front Cell Infect Microbiol. 2023;13:1142140.
18. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-61.
19. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20-30.
20. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72:2138-48.
21. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-52.
22. Liu J, Tian Y, Fu X, et al. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis. Chin Med J. 2022;135:1682-91.
23. Xiao J, Ng CH, Chan KE, et al. Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD - an umbrella overview of systematic review of meta-analysis. J Clin Exp Hepatol. 2023;13:656-65.
24. Stepanova M, De Avila L, Afendy M, et al. Direct and indirect economic burden of chronic liver disease in the United States. Clin Gastroenterol Hepatol. 2017;15:759-66.e5.
25. Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hepatol Int. 2020;14:556-66.
26. Perazzo H, Pacheco AG, Griep RH. Collaborators. Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J Hepatol. 2024;80:e72-4.
27. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7-11.
28. Arabi T, Shafqat A, Sabbah BN, et al. Obesity-related kidney disease: Beyond hypertension and insulin-resistance. Front Endocrinol. 2022;13:1095211.
29. Zheng J, Zhang Y, Rasheed H, et al. Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. Int J Epidemiol. 2022;50:1995-2010.
30. Tsao HM, Lai TS, Chang YC, et al. Serum urate and risk of chronic kidney disease: a mendelian randomization study using Taiwan biobank. Mayo Clin Proc. 2023;98:513-21.
31. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092.
32. Kim S, Chang Y, Sung E, et al. Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study. PLoS One. 2017;12:e0184506.
33. Liu Z, Wang Q, Huang H, Wang X, Xu C. Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study. Diabetol Metab Syndr. 2023;15:27.
34. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322:1294-304.
35. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398:786-802.
36. Sanchez-Niño MD, Sanz AB, Ramos AM, Ruiz-Ortega M, Ortiz A. Translational science in chronic kidney disease. Clin Sci. 2017;131:1617-29.
37. Gandjour A, Armsen W, Wehmeyer W, Multmeier J, Tschulena U. Costs of patients with chronic kidney disease in Germany. PLoS One. 2020;15:e0231375.
38. Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18:259-68.
39. Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: an updated narrative review. Int J Mol Sci. 2022;23:7007.
40. Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol. 2022;28:5691-706.
41. Sun DQ, Targher G, Byrne CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12:386-403.
42. Nysather J, Kaya E, Manka P, Gudsoorkar P, Syn WK. Nonalcoholic fatty liver disease and chronic kidney disease cross talk. Adv Kidney Dis Health. 2023;30:315-35.
43. Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci. 2022;23:13320.
44. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.
45. Liu HW, Liu JS, Kuo KL. Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan. Ci Ji Yi Xue Za Zhi. 2020;32:65-9.
46. Akahane T, Akahane M, Namisaki T, et al. Association between non-alcoholic fatty liver disease and chronic kidney disease: a cross-sectional study. J Clin Med. 2020;9:1635.
47. Deng Y, Zhao Q, Gong R. Association between metabolic associated fatty liver disease and chronic kidney disease: a cross-sectional study from NHANES 2017-2018. Diabetes Metab Syndr Obes. 2021;14:1751-61.
49. Su W, Chen M, Xiao L, et al. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. Front Public Health. 2022;10:1047794.
50. Agustanti N, Soetedjo NNM, Damara FA, et al. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17:102780.
51. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156-62.
52. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156-62.
53. Yi M, Peng W, Feng X, et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther. 2022;56:1119-30.
54. Tanaka M, Mori K, Takahashi S, et al. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transplant. 2023;38:700-11.
55. Jung CY, Koh HB, Park KH, et al. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. Diabetes Metab. 2022;48:101344.
56. Hashimoto Y, Hamaguchi M, Okamura T, et al. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig. 2022;13:308-16.
57. Zhang Y, Zhang T, Liu Y, et al. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: results from two prospective cohorts. Diabetes Metab Syndr. 2023;17:102873.
58. Pan LL, Zhang HJ, Huang ZF, et al. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: a cross-sectional study. Metabolism. 2015;64:1077-85.
59. Zuo G, Xuan L, Xin Z, et al. New nonalcoholic fatty liver disease and fibrosis progression associate with the risk of incident chronic kidney disease. J Clin Endocrinol Metab. 2021;106:e3957-68.
60. Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: a systematic review and meta-analysis. Biomolecules. 2022;12:105.
61. Seo DH, Suh YJ, Cho Y, et al. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J. 2022;46:630-9.
62. Sun Y, Hong L, Huang Z, et al. Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients. J Clin Endocrinol Metab. 2022;107:e3661-9.
63. Chung GE, Han K, Lee KN, et al. Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: a nationwide population-based study. Diabetes Metab. 2023;49:101454.
64. Lonardo A. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers. Expert Rev Clin Pharmacol. 2023;16:891-911.
65. Machado MV, Michelotti GA, Xie G, et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One. 2015;10:e0127991.
67. Wentworth BJ, Caldwell SH. Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common. Metab Target Organ Damage. 2021;1:2.
68. Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin Liver Dis. 2021;41:421-34.
69. Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity. World J Hepatol. 2021;13:1584-610.
70. Lonardo A, Singal AK, Osna N, Kharbanda KK. Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction. Metab Target Organ Damage. 2022;2:12.
71. Baratta F, D'Erasmo L, Bini S, et al. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): implication for cardiovascular risk stratification. Atherosclerosis. 2022;357:51-9.
72. Pirola CJ, Sookoian S. Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making. Expert Rev Gastroenterol Hepatol. 2023;17:317-24.
73. Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol. 2020;72:1196-209.
74. Lonardo A. Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies. Explor Dig Dis. ;2:188-201.
75. Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2020;40:107-19.
76. Mantovani A, Taliento A, Zusi C, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings. Liver Int. 2020;40:1130-41.
77. Akuta N, Kawamura Y, Arase Y, et al. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. BMC Gastroenterol. 2021;21:434.
78. Mantovani A, Pelusi S, Margarita S, et al. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction. Aliment Pharmacol Ther. 2023;57:1093-102.
79. Mantovani A, Targher G. PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease? Metab Target Organ Damage. 2023;3:18.
80. Lonardo A, Ballestri S, Targher G. "Not all forms of NAFLD were created equal". Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis? Atherosclerosis. 2017;257:253-5.
81. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;7:421-35.
82. Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22 Suppl 1:3-15.
83. Iqbal J, Wu HX, Nawaz MA, et al. Risk of incident chronic kidney disease in metabolically healthy obesity and metabolically unhealthy normal weight: a systematic review and meta-analysis. Obes Rev. 2024;25:e13656.
85. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of oxidative stress in metabolic syndrome. Int J Mol Sci. 2023;24:7898.
86. Stenvinkel P, Chertow GM, Devarajan P, et al. Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney Int Rep. 2021;6:1775-87.
87. Dorotea D, Koya D, Ha H. Recent insights into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways. Front Pharmacol. 2020;11:265.
88. Avraham S, Korin B, Chung JJ, Oxburgh L, Shaw AS. The mesangial cell - the glomerular stromal cell. Nat Rev Nephrol. 2021;17:855-64.
89. Costantino VV, Gil Lorenzo AF, Bocanegra V, Vallés PG. Molecular mechanisms of hypertensive nephropathy: renoprotective effect of losartan through Hsp70. Cells. 2021;10:3146.
90. Eshraghi Y, Abedi M, Gheisari Y. Proteomics to metabolomics: a new insight into the pathogenesis of hypertensive nephropathy. Kidney Blood Press Res. 2023;48:710-26.
91. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032-45.
92. DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17:319-34.
93. Berfield AK, Andress DL, Abrass CK. IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function. Kidney Int. 2002;62:1229-37.
94. Guo Y, Xie G, Zhang X. Role of FXR in renal physiology and kidney diseases. Int J Mol Sci. 2023;24:2408.
95. Zhu JB, Xu S, Li J, et al. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury. Eur J Pharmacol. 2018;838:60-8.
96. Palladini G, Cagna M, Di Pasqua LG, et al. Obeticholic acid reduces kidney matrix metalloproteinase activation following partial hepatic ischemia/reperfusion injury in rats. Pharmaceuticals. 2022;15:524.
97. Gege C, Hambruch E, Hambruch N, Kinzel O, Kremoser C. Nonsteroidal FXR ligands: current status and clinical applications. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 167-205.
98. Andres-Hernando A, Lanaspa MA, Kuwabara M, et al. Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice. Am J Physiol Renal Physiol. 2019;317:F941-8.
99. Søgaard SB, Andersen SB, Taghavi I, et al. Super-resolution ultrasound imaging provides quantification of the renal cortical and medullary vasculature in obese zucker rats: a pilot study. Diagnostics. 2022;12:1626.
100. Hashemi L, Hsiung JT, Arif Y, et al. Serum low-density lipoprotein cholesterol and cardiovascular disease risk across chronic kidney disease stages (data from 1.9 million United States veterans). Am J Cardiol. 2022;170:47-55.
101. Baragetti A, Norata GD, Sarcina C, et al. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med. 2013;274:252-62.
102. Baragetti A, Ossoli A, Strazzella A, et al. Low plasma lecithin: cholesterol acyltransferase (LCAT) concentration predicts chronic kidney disease. J Clin Med. 2020;9:2289.
103. Guerra S, Mocciaro G, Gastaldelli A. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. Eur J Clin Invest. 2022;52:e13695.
104. Jia J, Dou P, Gao M, et al. Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health: a bidirectional mendelian randomization analysis. Diabetes. 2019;68:1747-55.
105. Mazidi M, Shekoohi N, Covic A, Mikhailidis DP, Banach M. Adverse impact of desulfovibrio spp. and beneficial role of anaerostipes spp. on renal function: insights from a mendelian randomization analysis. Nutrients. 2020;12:2216.
106. Luo Q, Hu Y, Chen X, Luo Y, Chen J, Wang H. Effects of gut microbiota and metabolites on heart failure and its risk factors: a two-sample mendelian randomization study. Front Nutr. 2022;9:899746.
107. Li N, Wang Y, Wei P, et al. Causal effects of specific gut microbiota on chronic kidney diseases and renal function-a two-sample mendelian randomization study. Nutrients. 2023;15:360.
108. Gagnon E, Mitchell PL, Manikpurage HD, et al. Impact of the gut microbiota and associated metabolites on cardiometabolic traits, chronic diseases and human longevity: a Mendelian randomization study. J Transl Med. 2023;21:60.
109. Pantazi AC, Kassim MAK, Nori W, et al. Clinical perspectives of gut microbiota in patients with chronic kidney disease and end-stage kidney disease: where do we stand? Biomedicines. 2023;11:2480.
110. Feng Z, Wang T, Dong S, et al. Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature. J Int Med Res. 2021;49:3000605211053276.
111. Di Paola R, De A, Izhar R, et al. Possible effects of uremic toxins p-cresol, indoxyl sulfate, p-cresyl sulfate on the development and progression of colon cancer in patients with chronic renal failure. Genes. 2023;14:1257.
112. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-Oxide: the good, the bad and the unknown. Toxins. 2016;8:326.
113. Zeng Y, Guo M, Fang X, et al. Gut microbiota-derived trimethylamine N-oxide and kidney function: a systematic review and meta-analysis. Adv Nutr. 2021;12:1286-304.
114. Papandreou C, Moré M, Bellamine A. Trimethylamine N-oxide in relation to cardiometabolic health-cause or effect? Nutrients. 2020;12:1330.
115. Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116:448-55.
116. Tao P, Ji J, Wang Q, Cui M, Cao M, Xu Y. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease. Front Immunol. 2022;13:1080456.
117. Portincasa P, Bonfrate L, Vacca M, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23:1105.
119. Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M. Free fatty acid receptors in health and disease. Physiol Rev. 2020;100:171-210.
120. Secor JD, Fligor SC, Tsikis ST, Yu LJ, Puder M. Free fatty acid receptors as mediators and therapeutic targets in liver disease. Front Physiol. 2021;12:656441.
121. Hidalgo MA, Carretta MD, Burgos RA. Long chain fatty acids as modulators of immune cells function: contribution of FFA1 and FFA4 receptors. Front Physiol. 2021;12:668330.
122. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013;145:396-406.e1.
123. Mazidi M, Katsiki N, Banach M. Higher plasma levels of valerate produced by gut microbiota may have a beneficial impact on renal function. J Am Nutr Assoc. 2023;42:534-40.
124. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec. 2008;291:684-92.
125. Francque S, Wamutu S, Chatterjee S, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int. 2010;30:365-75.
126. Francque S, Verrijken A, Mertens I, et al. Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. Int J Obes. 2011;35:270-8.
127. Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2017;45:332-44.
128. Bruinius JW, Hannan M, Chen J, et al. CRIC Study Investigators. Self-reported physical activity and cardiovascular events in adults with CKD: findings from the CRIC (chronic renal insufficiency cohort) study. Am J Kidney Dis. 2022;80:751-61.e1.
129. Hamada S, Takata T, Yamada K, et al. Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model. PLoS One. 2022;17:e0265461.
130. Bier A, Shapira E, Khasbab R, Sharabi Y, Grossman E, Leibowitz A. High-fructose diet increases renal ChREBPβ expression, leading to intrarenal fat accumulation in a rat model with metabolic syndrome. Biology. 2022;11:618.
131. Abbate M, Mascaró CM, Montemayor S, et al. Animal fat intake is associated with albuminuria in patients with non-alcoholic fatty liver disease and metabolic syndrome. Nutrients. 2021;13:1548.
132. Meléndez-Salcido CG, Ramírez-Emiliano J, Pérez-Vázquez V. Hypercaloric diet promotes metabolic disorders and impaired kidney function. Curr Pharm Des. 2022;28:3127-39.
133. Mann JP, Savage DB. What lipodystrophies teach us about the metabolic syndrome. J Clin Invest. 2019;129:4009-21.
134. Kalavalapalli S, Leiva EG, Lomonaco R, et al. Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD. J Clin Endocrinol Metab. 2023;108:1192-201.
135. Mocciaro G, Gastaldelli A. Obesity-related insulin resistance: the central role of adipose tissue dysfunction. In: Eckel J, Clément K, editors. From Obesity to Diabetes. Cham: Springer International Publishing; 2022. pp. 145-64.
136. Koppe L, Soulage CO. The impact of dietary nutrient intake on gut microbiota in the progression and complications of chronic kidney disease. Kidney Int. 2022;102:728-39.
137. Yang M, Chen W, He L, Liu D, Zhao L, Wang X. Intermittent fasting-a healthy dietary pattern for diabetic nephropathy. Nutrients. 2022;14:3995.
138. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78.e5; quiz e14.
139. Ruggenenti P, Abbate M, Ruggiero B, et al. CRE.S.O. Study Group. . Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial. Diabetes. 2017;66:75-86.
140. Sumida K, Pierre JF, Yuzefpolskaya M, Colombo PC, Demmer RT, Kovesdy CP. Gut microbiota-targeted interventions in the management of chronic kidney disease. Semin Nephrol. 2023;43:151408.
141. Coutinho-Wolino KS, Melo MFS, Mota JC, Mafra D, Guimarães JT, Stockler-Pinto MB. Blueberry, cranberry, raspberry, and strawberry as modulators of the gut microbiota: target for treatment of gut dysbiosis in chronic kidney disease? Nutr Rev. 2024;82:248-61.
142. Juszczak F, Vlassembrouck M, Botton O, et al. Delayed exercise training improves obesity-induced chronic kidney disease by activating AMPK pathway in high-fat diet-fed mice. Int J Mol Sci. 2020;22:350.
143. Jung CY, Chun HS, Lee M, et al. Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: a nationwide cohort study. Diabetes Metab. 2022;48:101362.
144. Zheng T, Wang X, Kamili K, et al. The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol. 2024;Online ahead of print:1-9.
145. Wright WL, Urquhart S, Brunton S. Beyond blood glucose and blood pressure control in type 2 diabetes: alternative management strategies to prevent the development and progression of CKD. J Prim Care Community Health. 2023;14:21501319231153599.
146. Brar S, Ye F, James MT, Harrison TG, Pannu N. Interdisciplinary Chronic Disease Collaboration (ICDC). Processes of care after hospital discharge for survivors of acute kidney injury: a population-based cohort study. Am J Kidney Dis. 2024;83:216-28.
147. Maxson R, Starr J, Sewell J, Lyas C. SGLT2 inhibitors to slow chronic kidney disease progression: a review. Clin Ther. 2024;46:e23-8.
148. Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29:77-98.
149. Zhou H, Toshiyoshi M, Zhao W, Zhao Y, Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine. 2023;102:e33981.
150. Jin Z, Yuan Y, Zheng C, Liu S, Weng H. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023;37:108558.
151. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med. 2011;43:167-71.
152. Spasovski G, Rroji M, Hristov G, Bushljetikj O, Spahia N, Rambabova Bushletikj I. A new hope on the horizon for kidney and cardiovascular protection with SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists in type 2 diabetic and chronic kidney disease patients. Metab Syndr Relat Disord. 2024:Online ahead of print.
153. Sumida Y, Yoneda M, Toyoda H, et al. Common drug pipelines for the treatment of diabetic nephropathy and hepatopathy: can we kill two birds with one stone? Int J Mol Sci. 2020;21:4939.
154. Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 2023;8:943-54.
155. Schnell O, Battelino T, Bergenstal R, et al. CVOT summit 2022 report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22:59.
156. Lin DS, Lee JK, Hung CS, Chen WJ. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia. 2021;64:2676-86.
157. Banerjee M, Pal R, Maisnam I, Mukhopadhyay S. GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis. Diabetes Metab Syndr. 2024;18:102943.
158. Brockmeyer M, Parco C, Vargas KG, et al. Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data. J Nephrol. 2024:Online ahead of print.
159. DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022;24:1197-205.
160. Agarwal R, Filippatos G, Pitt B, et al. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84.
161. Adamson C, Jhund PS. Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. Eur Heart J. 2022;43:485-7.
162. Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPARα modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26:389-402.
163. Horinouchi Y, Murashima Y, Yamada Y, et al. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci. 2023;321:121590.
164. Iwasaki M, Suzuki H, Umezawa Y, et al. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study. Medicine. 2023;102:e32818.
165. Hadjivasilis A, Kouis P, Kousios A, Panayiotou A. The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies. J Clin Med. 2022;11:768.
166. Yokote K, Yamashita S, Arai H, et al. Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα), in dyslipidemic patients with renal impairment. Int J Mol Sci. 2019;20:706.
167. Goto H, Iseri K, Hida N. Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2023;Online ahead of print:gfad248.
168. Kim DH, Park JS, Choi HI, et al. The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD. Cell Death Dis. 2021;12:320.
169. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956-65.
170. Ratziu V, Harrison SA, Loustaud-Ratti V, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023;78:479-92.
171. Dalbeni A, Garbin M, Zoncapè M, et al. Glomerular hyperfiltration: a marker of fibrosis severity in metabolic associated steatotic liver disease in an adult population. Int J Mol Sci. 2023;24:15837.
172. Golabi P, Paik JM, Kumar A, et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States. Metabolism. 2023;146:155642.
173. Chung GE, Han K, Lee KN, et al. Combined effects of chronic kidney disease and nonalcoholic fatty liver disease on the risk of cardiovascular disease in patients with diabetes. Biomedicines. 2022;10:1245.
174. Hydes TJ, Kennedy OJ, Buchanan R, et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Med. 2023;21:185.
175. Li Y, Wu S, Gao J, et al. Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD. Am J Kidney Dis. 2024;83:477-88.
176. Triozzi JL, Richardson PA, Gregg LP, Navaneethan SD. Incidence and predictors of non-alcoholic fatty liver disease among patients with chronic kidney disease. Nephrol Dial Transplant. 2021;36:1546-8.
177. Wong F, Reddy KR, O'Leary JG, et al. Impact of chronic kidney disease on outcomes in cirrhosis. Liver Transpl. 2019;25:870-80.
178. Nascimbeni F, Pellegrini E, Lugari S, et al. Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes. Atherosclerosis. 2019;284:66-74.
179. Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Adv Ther. 2016;33:291-319.
180. Kim HS, Lee J, Kim EH, et al. Association of myosteatosis with nonalcoholic fatty liver disease, severity, and liver fibrosis using visual muscular quality map in computed tomography. Diabetes Metab J. 2023;47:104-17.
181. Arrese M, Cabello-verrugio C, Arab JP, et al. Sarcopenia in the setting of nonalcoholic fatty liver. Metab Target Organ Damage. 2022;2:2.
182. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157-72.
183. Mace ML, Egstrand S, Morevati M, Olgaard K, Lewin E. New insights to the crosstalk between vascular and bone tissue in chronic kidney disease-mineral and bone disorder. Metabolites. 2021;11:849.
184. Lonardo A. Renaming NAFLD to MAFLD: Could the LDE system assist in this transition? J Clin Med. 2021;10:492.
185. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
186. Malhi H, Brown RS Jr, Lim JK, et al. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: implications for and expectations of AASLD journals. Hepatology. 2023;78:1680-1.
187. Di Sessa A, Guarino S, Umano GR, Miraglia Del Giudice E, Marzuillo P. MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage. J Hepatol. 2024;80:e87-9.
188. Kobayashi N, Tada T, Nishimura T, et al. Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis. Hepatol Res. 2023; doi: 10.1111/hepr.13994.
